发布求助
文献互助 智能选刊 最新文献

Biological Therapy for Inflammatory Bowel Disease最新文献

筛选
英文 中文
Inhibitors of Tumoral Necrosis Factor Alpha in Inflammatory Bowel Disease 炎性肠病肿瘤坏死因子α抑制剂的研究
Biological Therapy for Inflammatory Bowel Disease Pub Date : 2020-01-27 DOI: 10.5772/intechopen.90204
C. Sobrado, N. Queiroz, C. Perez
{"title":"Inhibitors of Tumoral Necrosis Factor Alpha in Inflammatory Bowel Disease","authors":"C. Sobrado, N. Queiroz, C. Perez","doi":"10.5772/intechopen.90204","DOIUrl":"https://doi.org/10.5772/intechopen.90204","url":null,"abstract":"The treatment of inflammatory bowel disease (IBD) has undergone a major paradigm shift in the last two decades with the introduction of biological drugs. Tumoral necrosis factor (TNF) antagonists were the first monoclonal antibodies available for treatment of IBD. New emerging concepts as early initiation of treatment during the “ opportunity window, ” and “ treat to target ” with a tight control strategy have contributed to optimum utilization of these drugs allowing better long-term outcomes for treated patients. This chapter aims to review all current pivotal data regarding efficacy and safety of infliximab, adalimumab, certolizumab pegol, and golimumab, as long as real life experience with these agents. Comparative efficacy among anti-TNF agents and the role of therapeutic drug monitoring in the management of IBD will also be discussed. Last, the authors present future perspectives with the drugs and position anti-TNF agents as viable therapeutic options in the current IBD therapeutic armamentarium.","PeriodicalId":426417,"journal":{"name":"Biological Therapy for Inflammatory Bowel Disease","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123370668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biological Therapy in the Prevention of Complications of Crohn 预防克罗恩病并发症的生物治疗
Biological Therapy for Inflammatory Bowel Disease Pub Date : 2020-01-17 DOI: 10.5772/intechopen.90557
D. Ortiz-Masia
{"title":"Biological Therapy in the Prevention of Complications of Crohn","authors":"D. Ortiz-Masia","doi":"10.5772/intechopen.90557","DOIUrl":"https://doi.org/10.5772/intechopen.90557","url":null,"abstract":"In recent years, the advent of biological agents has revolutionized the treatment of inflammatory bowel disease (IBD). TNF is a cytokine with a very important role in the pathogenesis of Crohn’s disease (CD), so it is a therapeutic target to highlight. The efficacy and safety of the anti-TNF, IFX and ADA is widely established, becoming two of the therapeutic pillars of CD. Today the experience with other more recent antibodies and stem cells therapy is more limited. Various limitations such as lack of studies, heterogeneity in inclusion criteria, and achievement of objectives make it difficult to establish which treatment is more appropriate in each case and even the superiority between drugs and/or cellular therapy. This chapter will compare the different currently available therapies with special interest in new therapies and their relationship in the prevention of complications of Crohn’s disease.","PeriodicalId":426417,"journal":{"name":"Biological Therapy for Inflammatory Bowel Disease","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128049581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-Integrins, Anti-Interleukin 12/23p40, and JAK Inhibitors for the Inflammatory Bowel Disease Treatment 抗整合素、抗白细胞介素12/23p40和JAK抑制剂治疗炎症性肠病
Biological Therapy for Inflammatory Bowel Disease Pub Date : 2019-12-24 DOI: 10.5772/intechopen.90536
K. M. Steigleder, F. L. P. Neto, Cristiane Kibune Nagasako, R. Leal
{"title":"Anti-Integrins, Anti-Interleukin 12/23p40, and JAK Inhibitors for the Inflammatory Bowel Disease Treatment","authors":"K. M. Steigleder, F. L. P. Neto, Cristiane Kibune Nagasako, R. Leal","doi":"10.5772/intechopen.90536","DOIUrl":"https://doi.org/10.5772/intechopen.90536","url":null,"abstract":"Inflammatory bowel diseases (IBD) present a broad inflammatory cascade that is sometimes difficult to control. Patients with ulcerative colitis (UC) and Crohn’s disease (CD) are exposed to intense and harmful effects that compromise their quality of life. There is a constant need for new classes of drugs that act on different fronts of inflammation control. Initially, biologics revolutionized inflammatory bowel disease treatment. Anti-tumor necrosis factor (anti-TNF) agents and infliximab, followed by adalimumab and certolizumab pegol, have been proven to induce clinical and endoscopic remission. However, some patients are primary nonresponders, and a significant proportion of initial responders lose response throughout the treatment. The emergence of new therapies, such as anti-integrins, anti-interleukins, and inhibitors of Janus kinase (JAK), can become an alternative option for patients with previous therapeutic failures, besides offering greater safety than other biological therapies up to now. Among anti-integrins, vedolizumab is the drug with proven efficacy in both induction and maintenance of remission and has local and selective action in the intestine. Ustekinumab repre-sents the group of anti-interleukins, acting to control interleukin-12 (IL12) and interleukin-23 (IL23). JAK inhibitors (tofacitinib) act on intracellular inflammatory mediators and have the advantage of being orally administered. of vedolizumab in patients with previous anti-TNF treatment. The study showed an advantage of","PeriodicalId":426417,"journal":{"name":"Biological Therapy for Inflammatory Bowel Disease","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125217804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biological Therapy for Inflammatory Bowel Diseases: Screening Prior to Initiating and How to Proceed When Surgery Is Necessary 炎症性肠病的生物治疗:开始前的筛选以及必要时如何进行手术
Biological Therapy for Inflammatory Bowel Disease Pub Date : 2019-11-20 DOI: 10.5772/intechopen.90001
M. L. S. Ayrizono, Priscilla S P Oliveira, J. J. Fagundes
{"title":"Biological Therapy for Inflammatory Bowel Diseases: Screening Prior to Initiating and How to Proceed When Surgery Is Necessary","authors":"M. L. S. Ayrizono, Priscilla S P Oliveira, J. J. Fagundes","doi":"10.5772/intechopen.90001","DOIUrl":"https://doi.org/10.5772/intechopen.90001","url":null,"abstract":"Biological therapy has revolutionized the management of inflammatory bowel disease (IBD) in the last 30 years. However, these drugs have side effects and adverse events. Before starting this therapy, it is necessary to screen for specific infectious diseases and monitoring protocols. Screening for human immunodeficiency virus, hepatitis C, hepatitis B, and Mycobacterium tuberculosis infections must be included. In addition, vaccination should be checked and updated if necessary. Despite the advent of biological therapy, a significant number of patients with IBD will need surgery in their lifetime due to either clinical intractability or disease complications. Many of them will be on biological therapy, and there is a consider-able controversy about adverse effects of biologics on surgical outcomes. In this chapter, we will approach the screening required to start this therapy and how to proceed when surgery is necessary in these patients.","PeriodicalId":426417,"journal":{"name":"Biological Therapy for Inflammatory Bowel Disease","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114095221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Mucosal Immunology in the Inflammatory Bowel Diseases 炎症性肠病的粘膜免疫学
Biological Therapy for Inflammatory Bowel Disease Pub Date : 2019-11-11 DOI: 10.5772/intechopen.90037
G. Degasperi
{"title":"Mucosal Immunology in the Inflammatory Bowel Diseases","authors":"G. Degasperi","doi":"10.5772/intechopen.90037","DOIUrl":"https://doi.org/10.5772/intechopen.90037","url":null,"abstract":"Inflammatory bowel disease (IBD) includes two major phenotypes, Crohn’s disease and ulcerative colitis, which have different clinical characteristics and immune response profiles. Dysregulation of the intestinal immune response with elevated secretion of proinflammatory cytokines is a hallmark of IBD. In this chapter, we will characterize the cells of the innate and adaptive immunity involved in the pathogenesis of IBD. Innate lymphoid cells as well as dendritic cells, neutrophils, macrophages, B cells and T cells, including Th1 and Th2, Th9 and Th17 cells will be specifically characterized in this scenario. The cross talks and cytokine-mediated regulation of these cells with emphasis on cytokines IL-17, IL-22 and IL-23 will also be emphasized. propria. These antigens can be recognize by TLR or captured by M cells. The exposure of immune cells to the luminal content induces TCD4 + activation, differentiation and inflammatory cytokine release as well as neutrophil recruitment. IgA-opsonized bacteria contributes to the inflammation induced by Fc α RI. Several environmental factors (diet, genetics, lifestyle) can modulate the microbiota composition and the activation of immune cells in the Ulcerative Colitis;","PeriodicalId":426417,"journal":{"name":"Biological Therapy for Inflammatory Bowel Disease","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127547814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Traditional Drugs: Mechanisms of Immunosuppressor and Corticosteroid Therapies for Inflammatory Bowel Diseases 传统药物:免疫抑制剂和皮质类固醇治疗炎症性肠病的机制
Biological Therapy for Inflammatory Bowel Disease Pub Date : 2019-10-30 DOI: 10.5772/intechopen.90009
C. R. B. Cardoso, Amanda de Castro Habka, C. Pinzan, Camilla N. S. Oliveira, Jefferson Luiz da Silva, M. Duarte-Silva
{"title":"Traditional Drugs: Mechanisms of Immunosuppressor and Corticosteroid Therapies for Inflammatory Bowel Diseases","authors":"C. R. B. Cardoso, Amanda de Castro Habka, C. Pinzan, Camilla N. S. Oliveira, Jefferson Luiz da Silva, M. Duarte-Silva","doi":"10.5772/intechopen.90009","DOIUrl":"https://doi.org/10.5772/intechopen.90009","url":null,"abstract":"The inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis are immunological dysfunctions of the gastrointestinal tract that develop because of multifactorial processes, including genetic predisposition, gut dysbio-sis, and excessive inflammation in susceptible subjects. These pathologies affect millions of people worldwide, with substantial impact on healthcare systems and patients’ quality of life. Considering the chronic inflammation that underlies the IBD presentation, the main treatment options are related to the control of patients’ inflammatory response, through immunosuppressor and modulatory therapies. Therefore, in this chapter we reviewed the main mechanisms associated with the treatments that are aimed at suppressing mucosal immunity and the effects of corticosteroid therapies in Crohn’s disease and ulcerative colitis.","PeriodicalId":426417,"journal":{"name":"Biological Therapy for Inflammatory Bowel Disease","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126003229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Role of TNF in the Pathogenesis of Inflammatory Bowel Disease TNF在炎性肠病发病机制中的作用
Biological Therapy for Inflammatory Bowel Disease Pub Date : 2019-02-15 DOI: 10.5772/INTECHOPEN.84375
M. Perše, Ana Unkovič
{"title":"The Role of TNF in the Pathogenesis of Inflammatory Bowel Disease","authors":"M. Perše, Ana Unkovič","doi":"10.5772/INTECHOPEN.84375","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.84375","url":null,"abstract":"Tumor necrosis factor (TNF) is a pleotropic cytokine involved in a wide range of pathological processes, including inflammatory bowel disease (IBD). In the past, TNF was recognized as a pro-inflammatory cytokine with deleterious effects. This has led to the development of anti-TNF drugs, which revolutionized the treatment of inflammatory disorders such as Crohn’s disease. However, in the past 20 years, clinical studies have shown that anti-TNF drugs are not always effective. Moreover, in some rare cases, anti-TNF drugs can even cause an aggravation of the disease. Nowadays, there is increasing evidence that TNF is not only detrimental but can also play an important role in health and the maintenance of homeostasis. The aim of this chapter is to briefly summarize the literature demonstrating the complex dichotomous role of TNF in IBD and discuss the role of anti-TNF drugs in the treatment of IBD.","PeriodicalId":426417,"journal":{"name":"Biological Therapy for Inflammatory Bowel Disease","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128032831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信